Treatment for type 2 diabetes is undergoing a significant shift in approach. An update to the National Institute for Health and Care Excellence (NICE) guideline NG28, which informs clinical policies in the United Kingdom, is refocusing therapeutic priorities: maintaining glucose control remains essential, but protecting the heart and kidneys from the start of treatment is now a clear priority. This change in focus reflects a growing understanding of the complex ways diabetes impacts overall health.
This shift isn’t happening in isolation, and in some ways differs from the recommendations of the American Diabetes Association (ADA), a leading reference point in the United States.
From Glycemic Control to Protecting Target Organs
For decades, the primary goal in managing type 2 diabetes has been to lower glycated hemoglobin (HbA1c) levels. The logic was straightforward: less glucose meant fewer complications.
But, cardiovascular outcome studies have transformed this perspective. Research now shows that a significant proportion of deaths in people with diabetes are due to cardiovascular disease and heart failure, not just high blood sugar alone.
The updated NICE guideline incorporates this evidence by recommending earlier use of medications with proven benefits for both the cardiovascular system and kidneys, particularly SGLT2 inhibitors, in patients at increased risk.
NICE vs. ADA: Similarities and Differences
1. Early Cardiovascular Protection
Both NICE and the ADA recognize the benefits of medication classes such as:
- SGLT2 inhibitors
- GLP-1 receptor agonists
Both organizations recommend prioritizing these medications in patients with:
- Established cardiovascular disease
- Heart failure
- Chronic kidney disease
The main difference lies in the operational emphasis.
The ADA, in its Standards of Care, adopts a highly individualized approach, allowing for broad flexibility in therapeutic choices, including considering obesity as a central factor when prioritizing GLP-1 medications.
NICE, as an organization with a strong analysis of cost-effectiveness within a public system (NHS), structures recommendations more closely tied to formal risk criteria and population-level economic impact.
In other words:
- ADA → clinical focus with broad therapeutic freedom.
- NICE → clinical focus + health system rationality.
2. Is Metformin Still First-Line?
The ADA continues to recommend metformin as the traditional initial therapy in most cases, barring contraindications or a high risk of cardiovascular issues, where SGLT2 or GLP-1 medications can be started earlier.
NICE expands the possibility of initiating SGLT2 medications sooner in certain patient profiles, especially when there is a relevant cardiovascular or renal risk.
This nuance is important: the British guideline makes the shift away from the exclusive centrality of metformin more explicit.
3. Glycemic Monitoring
The ADA has been expanding recommendations for the use of continuous glucose monitoring (CGM), even in patients not using insulin in certain contexts.
NICE adopts a more restrictive stance, generally based on cost-effectiveness within the British public system.
4. Body Weight as a Central Axis
The ADA strongly emphasizes obesity as a priority therapeutic target, advocating for aggressive weight loss goals and the use of specific therapies for weight reduction.
NICE recognizes the importance of weight but maintains a therapeutic structure more focused on cardiovascular and renal risk.
What Does This Mean for Brazil?
In Brazil, where more than 10% of the adult population lives with diabetes and nearly half of patients may have associated cardiovascular disease, this discussion is not merely academic. The findings could influence treatment strategies and improve patient outcomes.
The situation is a hybrid one:
- Public system with budgetary limitations
- Private sector with increasing access to innovative therapies
- High prevalence of obesity and cardiometabolic risk
The NICE guideline can serve as a model for technology incorporation decisions within the SUS (Brazil’s public health system), while the ADA recommendations align more directly with individualized clinical practice in the private sector.
A Change Larger Than It Seems
We are witnessing something bigger than a simple protocol update.
Type 2 diabetes is no longer being treated solely as a glycemic disorder and is increasingly recognized as a systemic cardiometabolic syndrome, where the goal isn’t just to lower numbers, but to reduce mortality and preserve vital organs.
The convergence between NICE and the ADA reinforces that this isn’t a local trend, but a global movement based on robust evidence. The divergence, in turn, reveals something equally important: science and health policy go hand in hand, and clinical decisions are also economic and structural decisions.
*Written by Filippo Pedrinola, MD (CRM/SP 62253 | RQE 26961), National Head of Endocrinology at Brazil Health.
